OneMedNet Corp
ONMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ONMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONMD
OneMedNet Corp (ONMD) is a life sciences company focused on providing regulatory-grade real-world data (RWD) and AI-enabled solutions for clinical research, currently facing significant liquidity challenges and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
OneMedNet Corp (ONMD) is a life sciences company focused on providing regulatory-grade real-world data (RWD) and AI-enabled solutions for clinical research, currently facing significant liquidity challenges and a going concern uncertainty.
- Cash & equivalents of $0.4M as of 2026-06-30 [sec].
- Total revenue of $0.3M and net loss of -$2.2M for the six months ended 2026-06-30 [sec].
- Accumulated deficit of $106.8M as of 2026-03-31 [sec].
- Shareholders' equity of -$3.0M as of 2026-06-30 [sec].
- Management states cash is not sufficient to meet foreseeable needs for at least 12 months, raising substantial doubt about going concern [sec_mda · as of 2026-08-14].
What works
- The company has a wholly owned subsidiary, OneMedNet Technologies (Canada) Inc., indicating an established operational structure [sec · filed 2026-07-01].
- Management intends to raise cash through debt and equity offerings, suggesting ongoing efforts to secure financing [sec_mda · as of 2026-08-14].
What to weigh
- Recurring net losses since inception, with a net loss of $2.2M in the latest six-month period [sec].
- Cash of $0.4M is insufficient to fund operations for at least 12 months, creating a going concern risk [sec_mda · as of 2026-08-14].
- Total debt of $0.8M and accounts payable of $3.5M due within one year, exceeding available cash [sec_mda · as of 2026-08-14].
- Shareholders' equity is negative (-$3.0M), indicating a deficit in net assets [sec].
From the filings
Quoted directly from source documents.
The company has incurred recurring net losses and has a significant accumulated deficit.
“The Company has incurred recurring net losses since its inception, including $ 2.5 million and $ 1.9 million for the three months ended March 31, 2026 and 2025, respectively. In addition, the Company had an accumulated deficit of $ 106.8 million as of March 31, 2026.”
SEC filings · July 1, 2026
Management does not believe cash is sufficient for the next 12 months, raising going concern doubt.
“Currently, management does not believe that cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months.”
SEC filings · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Cash insufficient for 12 months; management expresses substantial doubt about ability to continue [sec_mda · as of 2026-08-14].
- Liquidity and capital needs — Cash of $0.4M vs. $4.0M in near-term obligations; may not raise funds on acceptable terms [sec_mda · as of 2026-08-14].
- Recurring operating losses — Net loss of $2.2M in latest six months; accumulated deficit of $106.8M [sec].
- Negative shareholders' equity — Equity of -$3.0M indicates liabilities exceed assets [sec].
What to watch
- Ability to raise additional capital through debt or equity offerings [sec_mda · as of 2026-08-14].
- Trend in revenue growth and operating expense management [sec].
- Any updates on going concern status or material changes in cash position [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated August 20, 2026 · How we verify sources →
Run OneMedNet Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OneMedNet Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.0 months
OCF -$2M · Net income -$2M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
10 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$10.1M
| Holder | Shares | Value |
|---|---|---|
| exencial wealth advisors, llc | 8,377,559 | $7.1M |
| vanguard capital management llc | 2,231,130 | $1.9M |
| geode capital management, llc | 338,528 | $288K |
| vanguard fiduciary trust co | 136,613 | $116K |
| citigroup inc | 135,445 | $115K |
| state street corp | 116,700 | $99K |
| discovery capital management, llc / ct | 112,252 | $95K |
| jane street group, llc | 111,740 | $95K |
| blackrock, inc. | 70,096 | $60K |
| northern trust corp | 54,944 | $47K |
Showing top 10 of 21 institutional holders of OneMedNet Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 2.7%
- Days to cover
- 0.8
- Shares short
- 743,681
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for OneMedNet Corp?
OneMedNet Corp (ONMD) is a life sciences company focused on providing regulatory-grade real-world data (RWD) and AI-enabled solutions for clinical research, currently facing significant liquidity challenges and a going concern uncertainty.
Who is the CEO of OneMedNet Corp?
Mr. Aaron Green is the chief executive officer of OneMedNet Corp (ONMD).
Where is OneMedNet Corp headquartered?
OneMedNet Corp (ONMD) is headquartered in Eden Prairie, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.